JPH0789876A - Sustained release preparation - Google Patents
Sustained release preparationInfo
- Publication number
- JPH0789876A JPH0789876A JP5265341A JP26534193A JPH0789876A JP H0789876 A JPH0789876 A JP H0789876A JP 5265341 A JP5265341 A JP 5265341A JP 26534193 A JP26534193 A JP 26534193A JP H0789876 A JPH0789876 A JP H0789876A
- Authority
- JP
- Japan
- Prior art keywords
- sustained
- release
- release preparation
- hormone
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は結晶セルロース、オイド
ラギットを含む担体に生理活性物質を含有せしめた徐放
性製剤に関する。更には脂肪酸、ろう類および／または
油脂類を加えることによって徐放速度を調整することが
できる製剤でもある。特にこの製剤を体内に埋め込むこ
とにより、静脈内投与や局所投与等によっては治療効果
の期待できない病態に対し効果を示すことの出来る体内
埋め込み型の徐放性製剤、具体的には脳内埋め込み型の
徐放性製剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a sustained release preparation containing a physiologically active substance in a carrier containing crystalline cellulose and Eudragit. Furthermore, it is also a preparation in which the sustained release rate can be adjusted by adding fatty acids, waxes and / or oils and fats. In particular, by implanting this preparation in the body, it can be effective in the pathological condition where the therapeutic effect cannot be expected by intravenous administration or local administration. The present invention relates to a sustained release preparation.
【０００２】[0002]
【従来の技術】医薬品を生体内に投与した場合に、生体
内での医薬品の溶出を制御し、吸収を調節する徐放性製
剤は古くから検討されている。例えば薬物を種々の被膜
で被覆する方法、あるいは薬物をワックスまたは高分子
のマトリックス中に包含させる方法等が知られている。2. Description of the Related Art Sustained-release preparations that control the elution of a drug in the living body and regulate the absorption when the drug is administered in vivo have been studied for a long time. For example, a method of coating the drug with various coatings, a method of incorporating the drug in a wax or polymer matrix, and the like are known.
【０００３】そして、脳内疾患治療における静脈内薬物
投与は血液脳関門により脳内への薬物の移行が妨げられ
ている。また、脳内への薬物直接投与法としては手術時
にカテーテルを留置して脳内に持続的に薬物を送る方法
があるが装置が高価である上に感染の危険性も大である
ため信頼性のある方法とは言い難い。In intravenous drug administration for the treatment of intracerebral diseases, the transfer of the drug into the brain is hindered by the blood-brain barrier. In addition, there is a method of directly injecting a drug into the brain by indwelling a catheter at the time of surgery to continuously deliver the drug into the brain, but the device is expensive and the risk of infection is high, so it is reliable. It is hard to say that there is a method.
【０００４】また、クモ膜下出血後に起こる遅発性脳血
管▲れん▼縮では病態が遅れて発症する上に持続的であ
るために薬物投与にカテーテルを挿入する方法や静脈内
に継続投与する方法が用いられている。しかしながら、
今だ確実な治療効果を得る方法は開発されていないのが
現状である。[0004] Further, in late-onset cerebral vasospasm that occurs after subarachnoid hemorrhage, the pathological condition is delayed and persistent, and therefore, a method for inserting a catheter into drug administration or continuous intravenous administration Method is used. However,
At present, no method has been developed to obtain a reliable therapeutic effect.
【０００５】[0005]
【発明が解決しょうとする課題】このような状況におい
て、薬物放出開始時期とその放出期間が調整できる製
剤、例えば投与後１日以上経過後薬物放出が開始され、
しかも薬物放出が５日以上もの長期にわたって持続する
ような製剤は投与回数を減らす上で好ましいが、いまま
では存在しなかった。キチンおよび／またはキトサンと
カルボキシビニルポリマーを利用した徐放性担体が提案
されているが、これは天然物を原料とするために、原料
の調達の確実性に欠ける難点がある。そしてその効果も
投与後３時間程で表れ、しかも１日も持続しないため、
効果の調節には物足りないものである。上記の事情から
わかるように原料の入手が確実で、簡単に調整できかつ
十分な徐放性が得られ、しかも放出開始時期を調節で
き、しかも長期にわたって薬物を放出することのできる
徐放性製剤の開発が望まれていた。In such a situation, a drug product whose release timing and release period can be adjusted, for example, drug release is started 1 day or more after administration,
In addition, a formulation that allows drug release to last for a long period of 5 days or more is preferable for reducing the number of administrations, but it has not existed until now. A sustained-release carrier using chitin and / or chitosan and a carboxyvinyl polymer has been proposed, but since this is a natural material, it has a drawback that the procurement of the raw material is not reliable. And the effect also appears about 3 hours after administration, and since it does not last for a day,
It is not enough to control the effect. As can be seen from the above circumstances, the sustained-release preparation, in which the raw materials are surely available, can be easily adjusted and has a sufficient sustained-release property, the release start time can be adjusted, and the drug can be released over a long period of time Was desired to be developed.
【０００６】[0006]
【課題を解決するための手段】そこで本発明者らが鋭意
研究した結果、結晶セルロースとオイドラギットを含む
担体を製剤化すれば良好な徐放性が得られることを見出
した。これに脂肪酸、ろう類および／または油脂類を加
えれば薬物の徐放速度をいかようにも（遅くにも速くに
も）調整でき、その上薬物の放出が１０日以上にもわた
って可能とすることができることが判明し、本発明を完
成するに至った。As a result of intensive studies by the present inventors, it was found that good sustained-release properties can be obtained by formulating a carrier containing crystalline cellulose and Eudragit. By adding fatty acids, waxes and / or oils and fats to this, the sustained release rate of the drug can be adjusted at any time (slow or fast), and the drug can be released over 10 days or more. It has been found that the present invention can be achieved, and the present invention has been completed.
【０００７】すなわち、本発明によれば、 １ 結晶セルロース、オイドラギットを含む担体に生理
活性物質を含有せしめてなることを特徴とする徐放性製
剤、 ２ 脂肪酸、ろう類および／または油脂類を加えてなる
１に記載の徐放性製剤、 ３ 生理活性物質が生理活性ペプチドである１ないし２
に記載の徐放性製剤、 ４ 生理活性ペプチドがカルシトニン遺伝子関連ペプチ
ドである３に記載の徐放性製剤、 ５ 油脂が硬化油である２に記載の徐放性製剤、 ６ 脂肪酸がステアリン酸である２に記載の徐放性製
剤、が得られる。That is, according to the present invention, 1 a sustained-release preparation characterized by containing a physiologically active substance in a carrier containing crystalline cellulose and Eudragit, 2 a fatty acid, a wax and / or an oil / fat is added. The sustained-release preparation according to 1, wherein 1 to 2 wherein the physiologically active substance is a physiologically active peptide
The sustained-release preparation according to claim 4, 4 the sustained-release preparation according to 3, wherein the physiologically active peptide is a calcitonin gene-related peptide, 5 the sustained-release preparation according to 2, wherein the fat or oil is hydrogenated oil, 6 the fatty acid is stearic acid The sustained release preparation according to item 2 is obtained.
【０００８】本発明において用いられる結晶セルロース
の配合量は制限的ではなく、放出開始時間及び放出持続
時間を考慮して定められるが、一般的に１０重量％−９
０重量％、好ましくは４０重量％−８０重量％である。The blending amount of the crystalline cellulose used in the present invention is not limited and is determined in consideration of the release initiation time and the release duration, but generally 10% by weight-9.
It is 0% by weight, preferably 40% -80% by weight.
【０００９】オイドラギットとはポリアクリル酸のエス
テル誘導体の一種であるが、この種類に属する全てのオ
イドラギットが使用可能である。オイドラギットを加え
ることによって生理活性物質の結晶セルロースへの過剰
な吸着を防ぎ、効率的に徐放させることができる。オイ
ドラギットの使用量は本発明の目的を達成するための量
であればよいので制限的ではないが、一般的には０．０
１重量％−１０重量％，好ましくは０．１重量％−５重
量％である。Eudragit is a kind of ester derivative of polyacrylic acid, and all Eudragit belonging to this class can be used. By adding Eudragit, it is possible to prevent the physiologically active substance from being excessively adsorbed on the crystalline cellulose and to effectively release it slowly. The amount of Eudragit used is not limited as long as it is an amount for achieving the object of the present invention, but it is generally 0.0
It is 1% by weight to 10% by weight, preferably 0.1% by weight to 5% by weight.
【００１０】脂肪酸としてはステアリン酸、ラウリン
酸、ミリスチン酸、イソステアリン酸、パルミチン酸、
ベヘニン酸等の炭素数１２−２２の化合物で、飽和また
は不飽和のカルボン酸である。それらのうちステアリン
酸が好ましい。その配合量は制限的ではなく、これも放
出開始時間及び放出持続時間を考慮して定められ、一般
的に１重量％−３０重量％、好ましくは１０重量％−２
５重量％である。As the fatty acid, stearic acid, lauric acid, myristic acid, isostearic acid, palmitic acid,
It is a compound having 12 to 22 carbon atoms such as behenic acid, which is a saturated or unsaturated carboxylic acid. Of these, stearic acid is preferred. The blending amount is not limited, and is also determined in consideration of the release initiation time and the release duration time, and is generally 1% by weight-30% by weight, preferably 10% by weight-2.
It is 5% by weight.
【００１１】油脂としては硬化油、カカオ脂、牛脂、豚
脂等が用いられる。それらのうち、硬化油が好ましい。
そしてその配合量は制限的ではなく、これも放出開始時
間及び放出持続時間を考慮して定められ、一般的に１重
量％−３０重量％、好ましくは１０重量％−２５重量％
である。As the fat and oil, hydrogenated oil, cacao butter, beef tallow, lard and the like are used. Of these, hydrogenated oils are preferred.
The blending amount is not limited, and is also determined in consideration of the release start time and the release duration, and is generally 1% by weight to 30% by weight, preferably 10% by weight to 25% by weight.
Is.
【００１２】ろう類としては蜜ロウ、カルウナバロウ、
白ロウ等が用いられる。そしてその配合量は制限的では
なく、これも放出開始時間及び放出持続時間を考慮して
定められ、一般的に１重量％−３０重量％、好ましくは
１０重量％−２５重量％である。As waxes, beeswax, carnauba wax,
White wax or the like is used. The blending amount is not limited, and is also determined in consideration of the release start time and the release duration time, and is generally 1% by weight to 30% by weight, preferably 10% by weight to 25% by weight.
【００１３】生理活性物質としてはなんら制限されない
が、例えばアドレナリン、アブシジン酸、アルギニンバ
ソトシン、アンギオテンシノーゲン、アンギオテンシ
ン、アンギオテンシンＩ変換酵素、胃液分泌抑制ポリペ
プチド、インシュリン、インシュリン様成長因子、Ｓ因
子、エリスロポエチン、黄体形成ホルモン、黄体形成ホ
ルモン放出ホルモン、黄体ホルモン、オキシトシン、２
−オクチル−γ−ブロモアセトアセテート、オータコイ
ド、ガストリン、ガストリン分泌促進ペプチド、The physiologically active substance is not limited at all, and examples thereof include adrenaline, abscisic acid, arginine vasotocin, angiotensinogen, angiotensin, angiotensin I converting enzyme, gastric secretion inhibitory polypeptide, insulin, insulin-like growth factor, S factor, Erythropoietin, luteinizing hormone, luteinizing hormone-releasing hormone, luteinizing hormone, oxytocin, 2
-Octyl-γ-bromoacetoacetate, autacoid, gastrin, gastrin secretagogue peptide,
【００１４】ガストロン、活性型ビタミンＤ３、カリジ
ン、カルシトニン、カルシトニン遺伝子関連ペプチド、
キニノーゲン、胸腺ホルモン、グルカゴン、グルココル
チコイト、血管作用性小腸ペプチド、血漿カリクレイ
ン、血清因子、血糖上昇ホルモン、甲状腺刺激ホルモ
ン、甲状腺刺激ホルモン放出ホルモン、甲状腺ホルモ
ン、黒色素胞刺激ホルモン、黒色素胞刺激ホルモン放出
ホルモン、黒色素胞刺激ホルモン放出抑制ホルモン、コ
ルチコトロピン様中葉ペプチド、ウロキナーゼ、Gastron, activated vitamin D 3 , kallidin, calcitonin, calcitonin gene-related peptide,
Kininogen, Thymic hormone, Glucagon, Glucocorticoid, Vasoactive intestinal peptide, Plasma kallikrein, Serum factor, Blood glucose increasing hormone, Thyroid stimulating hormone, Thyrotropin releasing hormone, Thyroid hormone, Melanophore stimulating hormone, Melanophore stimulating Hormone-releasing hormone, melanophore-stimulating hormone release inhibitory hormone, corticotropin-like intermediate lobe peptide, urokinase,
【００１５】コレシストキニンオクタペプチド、コレシ
ストキニンテトラペプチド、コレシストキニンバリアン
ト、コレシストキニン−１２、コレシストキニンパンク
レオチミン、コレシストキニン、細胞増殖因子、サブス
タンスＰ、雌性ホルモン、脂肪動員ホルモン、繊毛膜性
生殖腺刺激ホルモン、神経成長因子、膵ポリペプチド、
生殖巣刺激物質、生殖腺刺激ホルモン、成長ホルモン、
成長ホルモン放出因子、セクレチン、セルレイン、セロ
トニン、腺維芽細胞成長因子、Cholecystokinin octapeptide, cholecystokinin tetrapeptide, cholecystokinin variant, cholecystokinin-12, cholecystokinin pancreothymine, cholecystokinin, cell growth factor, substance P, female hormone, lipoattic hormone , Ciliary gonadotropin, nerve growth factor, pancreatic polypeptide,
Gonad stimulant, gonadotropin, growth hormone,
Growth hormone releasing factor, secretin, cerulein, serotonin, fibroblast growth factor,
【００１６】腺性カリクレイン、ソマトスタチン、ソマ
トメジンＡ、Ｂ、体色黒化・赤化ホルモン、胎盤性ラク
トゲン、チモシン、チモポイエチン、チログロブリン、
トラウマチン酸、内皮細胞成長因子、軟体動物性心臓興
奮性神経ペプチド、ニューロテンシン、妊馬血清性生殖
腺刺激ホルモン、脳ホルモン、ノルアドレナリン、バソ
プレッシン、発情ホルモン、ヒスタミン、表皮細胞成長
因子、副甲状腺ホルモン、副腎皮質刺激ホルモン、副腎
皮質刺激ホルモン放出因子、副腎皮質ホルモン、[0016] Glandular kallikrein, somatostatin, somatomedin A, B, body color-darkening / erythrogenic hormone, placental lactogen, thymosin, thymopoietin, thyroglobulin,
Traumatic acid, endothelial cell growth factor, mollusc cardiac excitatory neuropeptide, neurotensin, pregnant mare serum gonadotropin, brain hormone, noradrenaline, vasopressin, estrogen, histamine, epidermal growth factor, parathyroid hormone, Corticotropin, corticotropin-releasing factor, corticosteroid,
【００１７】ＰＡＣＡＰ、ブラジキニン，ブラジキニン
様ペプチド、プロインシュリン、プロオピオメラノコル
チン、プロスタグランジン、プロＰＴＨ、プロラクチ
ン、プロラクチン放出ホルモン、プロラクチン放出抑制
ホルモン、フロリゲン、閉経婦人尿生殖腺刺激ホルモ
ン、ボンベジン、マキサディラン、ミネラルコルチコイ
ド、明順応ホルモン、メチオニルリジルブラジキニン、
１−メチルアデニン、メラトニン、モチリン、雄性ホル
モン、利尿ホルモン、リポトロピン、レニン、レラクシ
ン、濾胞成熟ホルモン等が用いられる。PACAP, bradykinin, bradykinin-like peptide, proinsulin, proopiomelanocortin, prostaglandin, proPTH, prolactin, prolactin-releasing hormone, prolactin-releasing hormone, florigen, menopausal female gonadotropic hormone, bombedin, maxadilan, mineral Corticoid, photoadaptation hormone, methionyl lysyl bradykinin,
1-Methyladenine, melatonin, motilin, androgen, diuretic hormone, lipotropin, renin, relaxin, follicular maturation hormone and the like are used.
【００１８】その配合量は使用薬物と使用目的によりこ
となるが、一般的に０．０００１重量％−３０重量％で
ある。The blending amount varies depending on the drug used and the purpose of use, but is generally 0.0001% by weight to 30% by weight.
【００１９】製剤化にあたっては、公知のあらゆる製剤
技術が適用できる。そしてそのまま製剤化してもよい
が、従来公知の崩壊調整剤、安定剤、抗酸化剤、湿潤
剤、結合剤、滑沢剤等を加え、錠剤、丸剤、カプセル
剤、液剤等に製剤化する。For formulation, any known formulation technology can be applied. Although it may be formulated as it is, conventionally known disintegration regulators, stabilizers, antioxidants, wetting agents, binders, lubricants and the like are added to formulate tablets, pills, capsules, liquids and the like. .
【００２０】かくして得られる生理活性物質含有徐放性
製剤は体内、例えば、脳内に埋め込んで使用することが
できる画期的な製剤であるが、従来における経口投与、
経腸投与等の方法にも用いられる。The sustained-release preparation containing a physiologically active substance thus obtained is an epoch-making preparation which can be used by implanting it in the body, for example, in the brain.
It is also used in methods such as enteral administration.
【００２１】本発明の製剤は、剤型が崩壊することなく
薬剤のみが徐放されるという特徴を有している。The preparation of the present invention is characterized in that only the drug is gradually released without disintegrating the dosage form.
【００２２】[0022]
【実施例】以下に実施例をあげて本発明をさらに詳細に
説明するが、本発明はこれらにより制限されるものでは
なく、当業者において行われる変法、改良法も本発明の
範囲内に含まれることを理解しなければならない。The present invention will be described in more detail with reference to the following examples, but the present invention is not limited thereto, and modifications and improvements made by those skilled in the art are also within the scope of the present invention. It must be understood that it is included.
【００２３】［実施例１］ 徐放性製剤の製造（Ｉ） ０．４％カルシトニン遺伝子関連ペプチド（ＣＧＲＰ）
溶液２．５ｇ（ＣＧＲＰ１０ｍｇに相等）と１３ｇのオ
イドラギットを加えて混合し、次に結晶セルロース８７
ｇを加える。これらを十分混合した後、ＫＢｒ錠剤成型
器（１５０ｋｇ、１分）で直径１３ｍｍの平板錠剤を製
造した。[Example 1] Production of sustained-release preparation (I) 0.4% calcitonin gene-related peptide (CGRP)
2.5 g of solution (equal to 10 mg of CGRP) and 13 g of Eudragit were added and mixed, then crystalline cellulose 87
Add g. After thoroughly mixing these, flat tablets having a diameter of 13 mm were produced with a KBr tablet molding machine (150 kg, 1 minute).
【００２４】［実施例２］ 徐放性製剤の製造（ＩＩ） ステアリン酸１７ｇと硬化油（水添ヒマシ油）１７ｇを
混合し、これに０．４％カルシトニン遺伝子関連ペプチ
ド（ＣＧＲＰ）溶液２．０ｇ（ＣＧＲＰ８ｍｇに相等）
と０．３ｇのオイドラギットＬ３０Ｄ−５５を加えて混
合し、次に結晶セルロース６６ｇを加える。これらを十
分混合した後、ＫＢｒ錠剤成型器（１５０ｋｇ、１分）
で直径１３ｍｍの平板錠剤を製造した。Example 2 Production of sustained-release preparation (II) 17 g of stearic acid and 17 g of hydrogenated oil (hydrogenated castor oil) were mixed, and 0.4% calcitonin gene-related peptide (CGRP) solution 2. 0 g (equivalent to 8 mg of CGRP)
And 0.3 g of Eudragit L30D-55 are added and mixed, then 66 g of crystalline cellulose is added. After mixing them well, KBr tablet molding machine (150 kg, 1 minute)
A flat-plate tablet having a diameter of 13 mm was produced by.
【００２５】［実施例３］ 薬物放出試験（Ｉ） ハルトマン液５ｍｌを１５ｍｌ容チューブに無菌的に入
れる。その後、実施例１に得た錠剤を同様に無菌的にい
れ、３７℃、１２０ｒｐｍで振とうする。１、２、４、
７、１１、１４日目にサンプリングして高速液体クロマ
トグラフィーにて定量することにより薬剤放出量を求め
た。その結果を図１に示す。Example 3 Drug Release Test (I) 5 ml of Hartmann's solution is aseptically placed in a 15 ml tube. Thereafter, the tablets obtained in Example 1 are similarly aseptically put and shaken at 37 ° C. and 120 rpm. 1, 2, 4,
The drug release amount was determined by sampling on days 7, 11, and 14 and quantifying by high performance liquid chromatography. The result is shown in FIG.
【００２６】図中の番号は製剤の崩壊状態を示し、その
意味は以下のとおりである。 崩壊状態１：変化なし。 ２：２０％の膨潤がみられる。 ３：小さな亀裂がはいる。 ４：大きな亀裂がはいる。 ５：粉々になる。The numbers in the figure indicate the disintegrated state of the preparation, and their meanings are as follows. Collapsed state 1: No change. Swelling of 2: 20% is observed. 3: There are small cracks. 4: There is a big crack. 5: Shatter
【００２７】［実施例４］ 薬物放出試験（ＩＩ） 実施例３と同様にして、実施例２の製剤の放出試験を行
った。その結果を図２に示す。なお、番号の意味は前記
に同じである。Example 4 Drug Release Test (II) In the same manner as in Example 3, a release test of the preparation of Example 2 was conducted. The result is shown in FIG. The meaning of the numbers is the same as above.
【００２８】高速液体クロマトグラフィー条件は以下の
とおりである。The high performance liquid chromatography conditions are as follows.
【００２９】[0029]
【外１】 [Outer 1]
【００３０】[0030]
【発明の効果】本発明にかかる結晶セルロース、オイド
ラギットを含む担体に生理活性物質を含有せしめた徐放
性製剤、特に更に脂肪酸、ろう類および／または油脂類
を加えた製剤は製造が容易で、放出開始時間と放出期間
が調整できる優れた徐放活性を有する。EFFECTS OF THE INVENTION The sustained-release preparation in which a carrier containing crystalline cellulose and Eudragit according to the present invention contains a physiologically active substance, particularly a preparation in which a fatty acid, a wax and / or an oil / fat is further added, is easy to produce, It has excellent sustained-release activity with adjustable release start time and release period.
【図１】実施例１の製剤のＣＧＲＰの経時的検出％を示
す図である。FIG. 1 is a graph showing the% CGRP detection over time of the preparation of Example 1.
【図２】実施例２の製剤のＣＧＲＰの経時的検出％を示
す図である。FIG. 2 is a diagram showing% of CGRP detected over time in the preparation of Example 2.
フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 38/00 38/23 47/12 Ｃ 47/34 Ｃ 47/44 Ｃ (72)発明者 馬場 隆明 神奈川県横浜市金沢区福浦２丁目12番１号 株式会社資生堂第２リサーチセンター内 (72)発明者 渡部 一夫 神奈川県横浜市金沢区福浦２丁目12番１号 株式会社資生堂第２リサーチセンター内Continuation of the front page (51) Int.Cl. 6 Identification number Internal reference number in the agency FI Technical indication location A61K 38/00 38/23 47/12 C 47/34 C 47/44 C (72) Inventor Takaaki Baba Kanagawa Prefecture 2-12-1, Fukuura, Kanazawa-ku, Yokohama-shi Shiseido 2nd Research Center (72) Inventor Kazuo Watanabe 2-12-1, Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa Shiseido 2nd Research Center
Claims (6)
担体に生理活性物質を含有せしめてなることを特徴とす
る徐放性製剤。1. A sustained-release preparation comprising a carrier containing crystalline cellulose and Eudragit containing a physiologically active substance.
加えてなる請求項１に記載の徐放性製剤。2. The sustained-release preparation according to claim 1, which further comprises fatty acids, waxes and / or oils and fats.
請求項１ないし２に記載の徐放性製剤。3. The sustained-release preparation according to claim 1, wherein the physiologically active substance is a physiologically active peptide.
関連ペプチドである請求項３に記載の徐放性製剤。4. The sustained-release preparation according to claim 3, wherein the physiologically active peptide is a calcitonin gene-related peptide.
放性製剤。5. The sustained-release preparation according to claim 2, wherein the fat or oil is hydrogenated oil.
記載の徐放性製剤。6. The sustained-release preparation according to claim 2, wherein the fatty acid is stearic acid.
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5265341A JPH0789876A (en) | 1993-09-20 | 1993-09-20 | Sustained release preparation |
| KR1019940023738A KR950007873A (en) | 1993-09-20 | 1994-09-16 | Biologics Sustained-Release Pharmaceutical Formulations |
| AU73055/94A AU687423B2 (en) | 1993-09-20 | 1994-09-19 | Physiologically active substance-prolonged releasing-type pharmaceutical preparation |
| CA002132396A CA2132396A1 (en) | 1993-09-20 | 1994-09-19 | Physiologically active substance-prolonged releasing-type pharmaceuticalpreparation |
| US08/309,152 US5637309A (en) | 1993-09-20 | 1994-09-20 | Physiologically active substance-prolonged releasing-type pharmaceutical preparation |
| EP94114768A EP0645136A3 (en) | 1993-09-20 | 1994-09-20 | Physiologically active substance-prolonged releasing-type pharmaceutical preparation. |
| TW83110658A TW382598B (en) | 1993-09-20 | 1994-11-17 | Physiologically active substance-prolonged releasing-type pharmaceutical composition |
| AU55380/98A AU5538098A (en) | 1993-09-20 | 1998-02-19 | A slow releasing physiologically active pharmaceutical and method of preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5265341A JPH0789876A (en) | 1993-09-20 | 1993-09-20 | Sustained release preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0789876A true JPH0789876A (en) | 1995-04-04 |
Family
ID=17415838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5265341A Withdrawn JPH0789876A (en) | 1993-09-20 | 1993-09-20 | Sustained release preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0789876A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007517912A (en) * | 2004-01-13 | 2007-07-05 | バソジェニックス ファーマシューティカルズ， インコーポレイテッド | Controlled release CGRP delivery composition for cardiovascular and renal indications |
| JP2007517913A (en) * | 2004-01-13 | 2007-07-05 | バソジェニックス ファーマシューティカルズ， インコーポレイテッド | Method for treating acute myocardial infarction by administering calcitonin gene-related peptide and composition containing calcitonin gene-related peptide |
| WO2008102563A1 (en) * | 2007-02-23 | 2008-08-28 | Next21 K.K. | Therapeutic or prophylactic agent for vasoconstriction |
| JP2009538832A (en) * | 2006-05-22 | 2009-11-12 | ビオヒット・ユルキネン・オサケユキテュア | Compositions and methods for binding acetaldehyde in the stomach |
-
1993
- 1993-09-20 JP JP5265341A patent/JPH0789876A/en not_active Withdrawn
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007517912A (en) * | 2004-01-13 | 2007-07-05 | バソジェニックス ファーマシューティカルズ， インコーポレイテッド | Controlled release CGRP delivery composition for cardiovascular and renal indications |
| JP2007517913A (en) * | 2004-01-13 | 2007-07-05 | バソジェニックス ファーマシューティカルズ， インコーポレイテッド | Method for treating acute myocardial infarction by administering calcitonin gene-related peptide and composition containing calcitonin gene-related peptide |
| US7976847B2 (en) | 2004-01-13 | 2011-07-12 | Vasogenix Pharmaceuticals, Inc. | Controlled release CGRP delivery composition for cardiovascular and renal indications |
| JP2009538832A (en) * | 2006-05-22 | 2009-11-12 | ビオヒット・ユルキネン・オサケユキテュア | Compositions and methods for binding acetaldehyde in the stomach |
| WO2008102563A1 (en) * | 2007-02-23 | 2008-08-28 | Next21 K.K. | Therapeutic or prophylactic agent for vasoconstriction |
| US8283337B2 (en) | 2007-02-23 | 2012-10-09 | Next21 K.K. | Therapeutic or prophylactic agent for vasoconstriction |
| JP5781727B2 (en) * | 2007-02-23 | 2015-09-24 | 株式会社ネクスト２１ | Therapeutic or preventive agent for vasospasm |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3313113B2 (en) | Biocompatible implants for controlling ovulation in mares | |
| US5637309A (en) | Physiologically active substance-prolonged releasing-type pharmaceutical preparation | |
| DE69731957T2 (en) | ORAL PHARMACEUTICAL PRODUCTS WITH PEPTIDES | |
| CN101189022B (en) | Adrenocorticotropic hormone analogs and related methods | |
| Urquhart et al. | Rate-controlled delivery systems in drug and hormone research | |
| JP2003517014A (en) | Pharmaceutical implant containing immediate release and sustained release components and administration method | |
| WO1999042110A1 (en) | Regulation of estrus and ovulation in gilts | |
| US5342622A (en) | Subdermal biocompatible implants | |
| JPH05507493A (en) | Combination therapy with GnRH antagonists and GnRH to modulate gonadotropin levels in mammals | |
| EP0300982B1 (en) | Treatment of infertility | |
| JPH0789876A (en) | Sustained release preparation | |
| JPH07252166A (en) | Sustained release preparation | |
| JPH0797338A (en) | Sustained release preparation | |
| EA009210B1 (en) | Use of ln in controlled ovarian huperstimulation | |
| Armstrong et al. | Agonists of endogenous opioid peptides suppress LH, and stimulate cortisol and growth hormone during the follicular phase in heifers | |
| US4997825A (en) | Synergistic treatment method | |
| JPH05148154A (en) | Pharmaceutical containing physiologically active polypeptide | |
| TW382598B (en) | Physiologically active substance-prolonged releasing-type pharmaceutical composition | |
| US20030092628A1 (en) | Gonadotropin releasing hormone antagonist | |
| DK170758B1 (en) | Method of Increasing the Concentration of Endogenous Growth Hormone in the Blood of a Livestock Selected from Cattle, Pigs, Sheep, Goats, Camels and Horses | |
| CN111789936B (en) | Alarelin composition and preparation method thereof | |
| US7235524B2 (en) | Medicaments for initiating ovulation | |
| Duijkers et al. | Serum levels of follicle-stimulating hormone and luteinizing hormone after subcutaneous administration of human menopausal gonadotropin during pituitary suppression | |
| Sassolas et al. | Clinical studies with human growth hormone releasing factor in normal adults and patients | |
| CN115137809A (en) | Medicine containing adrenocorticotropic hormone and its derivative and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20001128 |